Sabby Management Lowered Paratek Pharmaceuticals (PRTK) Position By $975,000, Clean Harbors Has 1.08 Sentiment

June 14, 2017 - By Marguerite Chambers

Sabby Management Llc decreased Paratek Pharmaceuticals Inc (PRTK) stake by 37.14% reported in 2016Q4 SEC filing. Sabby Management Llc sold 65,000 shares as Paratek Pharmaceuticals Inc (PRTK)’s stock rose 33.85%. The Sabby Management Llc holds 110,000 shares with $1.69 million value, down from 175,000 last quarter. Paratek Pharmaceuticals Inc now has $618.54M valuation. It is 0.00% or $0 reaching $22.2 per share. It is down 62.03% since June 14, 2016 and is uptrending. It has outperformed by 45.33% the S&P500.

Clean Harbors, Inc. is a provider of environmental, energy and industrial services throughout North America. The company has market cap of $3.31 billion. The Firm is also a re-refiner and recycler of used oil in the world and a well-known provider of parts cleaning and related environmental services to commercial, industrial and automotive clients in North America. It currently has negative earnings. The Firm operates in six divisions: Technical Services, Industrial Services, Field Services, Safety-Kleen, Oil and Gas Field Services, and Lodging Services.

Analysts await Clean Harbors Inc (NYSE:CLH) to report earnings on August, 2. They expect $0.30 EPS, up 100.00% or $0.15 from last year’s $0.15 per share. CLH’s profit will be $17.08 million for 48.45 P/E if the $0.30 EPS becomes a reality. After $-0.19 actual EPS reported by Clean Harbors Inc for the previous quarter, Wall Street now forecasts -257.89% EPS growth.

Since January 1, 0001, it had 0 insider purchases, and 13 sales for $13.74 million activity.

About 57,564 shares traded. Clean Harbors Inc (CLH) has risen 18.53% since June 14, 2016 and is uptrending. It has outperformed by 1.83% the S&P500.

Ratings analysis reveals 60% of Clean Harbors’s analysts are positive. Out of 5 Wall Street analysts rating Clean Harbors, 3 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $49.0 while the high is $61.0. The stock’s average target of $54 is -7.12% below today’s ($58.14) share price. CLH was included in 5 notes of analysts from August 26, 2016. Needham maintained it with “Buy” rating and $61.0 target in Thursday, February 23 report. As per Monday, November 7, the company rating was downgraded by Barclays Capital. As per Tuesday, January 31, the company rating was upgraded by KeyBanc Capital Markets. Macquarie Research initiated Clean Harbors Inc (NYSE:CLH) rating on Friday, August 26. Macquarie Research has “Neutral” rating and $51.0 target. As per Monday, November 14, the company rating was maintained by Stifel Nicolaus.

Pivot Point Capital Partners Llc holds 17.17% of its portfolio in Clean Harbors Inc for 511,964 shares. Southernsun Asset Management Llc owns 3.94 million shares or 5.6% of their US portfolio. Moreover, 12Th Street Asset Management Company Llc has 4.3% invested in the company for 255,122 shares. The California-based Snyder Capital Management L P has invested 3.73% in the stock. Orbis Investment Management (U.S.) Llc, a California-based fund reported 76,268 shares.

Among 8 analysts covering Paratek Pharmaceuticals (NASDAQ:PRTK), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Paratek Pharmaceuticals had 12 analyst reports since July 23, 2015 according to SRatingsIntel. The stock has “Hold” rating by Zacks on Tuesday, September 22. H.C. Wainwright maintained the stock with “Buy” rating in Friday, June 17 report. Leerink Swann reinitiated Paratek Pharmaceuticals Inc (NASDAQ:PRTK) on Thursday, October 27 with “Outperform” rating. As per Saturday, August 8, the company rating was downgraded by Zacks. The company was upgraded on Wednesday, September 2 by Zacks. On Friday, May 13 the stock rating was initiated by Robert W. Baird with “Outperform”. The stock of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) earned “Outperform” rating by Wedbush on Tuesday, April 4. The stock of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) earned “Sell” rating by Zacks on Friday, August 14. Ladenburg Thalmann maintained the shares of PRTK in report on Friday, June 17 with “Buy” rating. The stock of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) earned “Hold” rating by Zacks on Saturday, August 22.

Investors sentiment decreased to 1.22 in 2016 Q4. Its down 0.61, from 1.83 in 2016Q3. It worsened, as 11 investors sold PRTK shares while 21 reduced holdings. 14 funds opened positions while 25 raised stakes. 14.91 million shares or 3.36% more from 14.42 million shares in 2016Q3 were reported. State Street reported 0% in Paratek Pharmaceuticals Inc (NASDAQ:PRTK). Aisling Ltd Llc invested in 1.73% or 482,680 shares. Jpmorgan Chase And accumulated 22,301 shares. Royal Bankshares Of Canada holds 0% of its portfolio in Paratek Pharmaceuticals Inc (NASDAQ:PRTK) for 849 shares. Manufacturers Life Insur The holds 13,671 shares. Nea Co Ltd holds 66,245 shares. Vanguard Gru reported 661,179 shares. Bankshares Of America Corporation De holds 0% of its portfolio in Paratek Pharmaceuticals Inc (NASDAQ:PRTK) for 8,686 shares. Morgan Stanley stated it has 59,450 shares. Sphera Funds Mgmt Ltd holds 0.55% of its portfolio in Paratek Pharmaceuticals Inc (NASDAQ:PRTK) for 140,000 shares. Rhumbline Advisers invested in 17,443 shares or 0% of the stock. Baupost Gru Ma holds 0.41% or 2.04M shares in its portfolio. Lpl Fincl Llc has 0% invested in Paratek Pharmaceuticals Inc (NASDAQ:PRTK). Blackrock Invest Mgmt Ltd Liability Corp stated it has 73,378 shares or 0% of all its holdings. 18,839 were accumulated by Prelude Cap Llc.

Sabby Management Llc increased Portola Pharmaceuticals Inc (Call) stake by 1,503 shares to 1,803 valued at $4.05 million in 2016Q4. It also upped Alnylam Pharmaceuticals Inc (Put) stake by 1,187 shares and now owns 2,056 shares. Pacira Pharmaceuticals Inc (Call) was raised too.